Non Small Cell Lung Cancer
Conditions
Brief summary
This is a Retrospective, Multicenter, Controlled Study to Evaluate Immunotherapy and Radiotherpay for Brain Lesions as a Potential Treatment for Patients with Brain Metastasis in non-small cell lung cancer
Interventions
In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan University
Sun Yat-sen University
Tongji Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Experimental group: 1. 18 years old ≤ age ≤ 75 years old, no gender limitation; 2. NSCLC who have received radiotherapy for brain lesions + PD-1/PD-L1 immunotherapy; 3. Histologically confirmed as NSCLC; 4. Imaging confirmed brain metastasis (CT or MRI); 5. The presence of imaging-evaluable lesions can be evaluated in accordance with RECIST 1.1 Control group: 1 18 years old ≤ age ≤ 75 years old, no gender limitation; 2 NSCLC who has received radiotherapy for brain lesions; 3 Histologically confirmed as non-small cell lung cancer; 4 Imaging confirmed brain metastasis (CT or MRI); 5 The presence of imaging-evaluable lesions can be evaluated in accordance with RECIST 1.1 \-
Exclusion criteria
1 The age is less than 18 years old, regardless of gender; 2 Histologically confirmed as NSCLC 3 Imaging confirmed the absence of brain metastases 4 NSCLC with brain metastasis only received chemotherapy or targeted therapy, and did not receive radiotherapy or immunotherapy \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free surival | 3 years | Progression-free survival: From the first treatment to the date of first documentation of disease progression, or death due to any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 3 years | Overall survival: From the first administration to death from any cause |
Countries
China
Outcome results
None listed